Cargando…

Initial Combination Empagliflozin and Linagliptin Improves Kidney Fibrotic Marker in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Background: Transforming growth factor-beta 1 (TGF- ß1) is a novel cytokine marker and also one of the therapeutic targets in the treatment of diabetic kidney disease. Both sodium glucose co-transporter 2 inhibitor and dipeptidyl-peptides 4 inhibitor reduce TGF- ß 1 level in animal studies, but whet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sathavarodom, Nattapol, Putthanuparp, Thanaporn, Pinphanichakarn, Verapon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089991/ http://dx.doi.org/10.1210/jendso/bvab048.848

Ejemplares similares

ODP222 Liragluitde Increased IL-1RA Concentrations in Obese Type 2 Diabetes: A Small Randomized Controlled Trial
por: Sathavarodom, Nattapol, et al.
Publicado: (2022)

Comparison Between Linagliptin and Canagliflozin Effect on Inflammatory Markers, CD34+ Cell Gene Expression and Urine Exosomes in Type 2 Diabetes Subjects
por: Nandula, Seshagiri R, et al.
Publicado: (2021)

Clinical Effectiveness and Safety of Gliclazide MR and Linagliptin Combination in the Management of Patients With T2DM and Chronic Kidney Disease (CKD) Switched From Glimepiride - a Real-World, Retrospective, Observational Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2021)

SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019)

SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
por: MS, ANEESH
Publicado: (2019)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

SAT-128 Evaluating the Accuracy of Glycemic Markers and Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease by Continuous Glucose Monitoring
por: Presswala, Lubaina, et al.
Publicado: (2019)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Fetuin-A as a Marker of NAFLD
por: Dharmalingam, Mala, et al.
Publicado: (2021)

THU371 Empagliflozin Associated Pancreatitis: A Case Report
por: Poloju, Alekya, et al.
Publicado: (2023)

Inpatient Hypoglycemia in Patients With Chronic Kidney Disease
por: Do, Justin, et al.
Publicado: (2021)

MON-137 A Case of Diabetic Striatopathy Initially Diagnosed as Intracerebral Hemorrhage
por: Alaigh, Vivek, et al.
Publicado: (2019)

MON-680 Might Podocyturia Be an Early Marker for Diabetic Nephropathy in Males
por: Durcan, Emre, et al.
Publicado: (2020)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

SAT-LB127 Regulation of ENaC by Exosomal Lipids in the Diabetic Kidney
por: Tuna, Kubra M, et al.
Publicado: (2020)

MON-132 DKA Accompanied with Concomitant Hypertriglyceridemia-Induced Acute Pancreatitis as Initial Presentation of Ketosis-Prone Diabetes
por: Monsour, Elio, et al.
Publicado: (2019)

MON-156 Association of Adhesion Molecule with Diabetes, Diabetic Retinopathy, and Diabetic Kidney Disease
por: Siddiqui, Khalid, et al.
Publicado: (2019)

MON-160 Effect Of The Combination Conjugated Estrogens And Bazedoxifene On Glucose Homeostasis In Obese Postmenopausal Women: A Placebo-controlled Randomized Pilot Trial
por: Lovre, Dragana, et al.
Publicado: (2019)

MON-171 Diabetics' Perceptions about Insulin Are Major Barriers to Its Early Initiation: A Cross-Sectional Study
por: Arshad, Iqra, et al.
Publicado: (2019)

Response to Twin Enabled Precision Treatment for Reversing Diabetes: An Initial Analysis at 4 Weeks of the Ongoing Randomised Controlled Trial
por: Shamanna, Paramesh, et al.
Publicado: (2021)

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
por: Shuster, Shirley, et al.
Publicado: (2021)

Chronic Kidney Disease Prevalence and Glomerular Filtration Rate Trends in Children With Type 1 Diabetes
por: Favel, Kristen, et al.
Publicado: (2021)

Pre-Conception Weight Loss Improves Reproductive, Metabolic and Kidney Health in Obese Mice and Their Offspring
por: Rodrigo, Natassia, et al.
Publicado: (2021)

MON-LB116 FGF-21 Is A Reliable Marker Of Insulin Resistance Before The Occurrence Of Glucose Intolerance
por: sawah, ahmed, et al.
Publicado: (2020)

SAT-LB109 Implementation of a Quality Improvement Initiative for Advanced Ketone Management in Children With Recently Diagnosed Type 1 Diabetes
por: Jindal, Ishita, et al.
Publicado: (2020)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

SAT-135 Risk Factors for Foot Problems among Patients with Type 2 Diabetes and Chronic Kidney Disease
por: Felipe, Roy Raoul
Publicado: (2019)

SAT-178 Parasitoid Wasp Venom Elevates Sorbitol and Alters Expression of Metabolic Genes in Human Kidney Cells
por: Siebert, Aisha, et al.
Publicado: (2019)

MON-661 Association of 25-Hydroxyvitamin D Serum Levels with Markers of Glycemic Control in Diabetic and Nondiabetic Patients on Maintenance Hemodialysis
por: Falcetta, Pierpaolo, et al.
Publicado: (2020)

MON-LB124 Euglycemic Diabetic Ketoacidosis on Initiation of Ertugliflozin in a Patient With Type 2 Diabetes Mellitus Precipitated by a Ketogenic Diet
por: Richstein, Ryan, et al.
Publicado: (2020)

Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State Associated With COVID 19
por: Naranjo, José Martín Alanís, et al.
Publicado: (2021)

PSUN250 Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes
por: Alzenaidi, Ahlam, et al.
Publicado: (2022)

OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience
por: Molitch, Mark, et al.
Publicado: (2019)

MON-692 Effect of High Salt Diet on Kidney Weight in Neonatal Streptozotocin Induced Noninsulin Dependent Diabetic Rats
por: Safta, Loren, et al.
Publicado: (2020)

Effect of Chronic Kidney Disease on Outcomes of Adult Patients Admitted With Hyperosmolar Hyperglycemic State: Analysis of National Inpatient Sample
por: Shaka, Hafeez, et al.
Publicado: (2021)

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes
por: Sato, Tetsuhiko, et al.
Publicado: (2021)

MON-639 Melanocortin 4 Receptor Contributes to Glucose Homeostasis by Regulating Kidney Glucose Reabsorption via the Glucose Transporter GLUT2
por: de Souza Cordeiro, Leticia M, et al.
Publicado: (2020)

Tgm2-p62-p53 Complex May Function as an Autophagic Regulator Through Fyn and Involve in Diabetic Kidney Disease
por: Uehara, Ryota, et al.
Publicado: (2021)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gpp94r3r8qua007871v558ns3i